You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 146 No. 8, August 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (13)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Immobilization Hypercalcemia Associated With Landry-Guillain-Barré Syndrome

Successful Therapy With Combined Calcitonin and Etidronate

Jay M. Meythaler, MD; Adel B. Korkor, MD; Thim Nanda, MD; Nirmal A. Kumar, MD; Michael Fallon, MD

Arch Intern Med. 1986;146(8):1567-1571.


Abstract

• Two patients with immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome had marked hypercalciuria (890 and 1136 mg/d [22.2 and 28.3 mmol/d]) and radiologic evidence of generalized osteopenia. Parathyroid hormone levels were either low or normal by C-terminal radioimmunoassay. Subtotal parathyroidectomy was performed in the one patient, with no improvement in serum or urinary calcium levels. A bone biopsy specimen revealed decreased cellular activity in the first patient and increased bone resorption in the second patient. Treatment with intravenous saline, furosemide, oral phosphate supplementation, mithramycin, and calcitonin alone was ineffective in lowering serum or urinary calcium levels. However, when subcutaneous calcitonin combined with oral etidronate disodium was used, a reduction in the serum calcium level was observed within two days of therapy. Within one week of the start of this combined therapy, the calcium level returned to normal and urinary calcium excretion was substantially reduced.

(Arch Intern Med 1986;146:1567-1571)



Author Affiliations

From the Departments of Physical Medicine and Rehabilitation (Drs Meythaler, Nanda, and Kumar) and Medicine (Nephrology Section) (Dr Korkor), Medical College of Wisconsin, Milwaukee; and the Department of Pathology, University of Pennsylvania, Philadelphia (Dr Fallon).


Footnotes

Accepted for publication Dec 18, 1985.

Read in part before the Midwest Regional Physiatric Conference, Chicago, April 20, 1985.

Reprint requests to Nephrology Section, Department of Medicine, Froedtert Memorial Lutheran Hospital, 9200 W Wisconsin Ave, Milwaukee, WI 53226 (Dr Korkor).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Supportive Care for Patients With Guillain-Barre Syndrome
Hughes et al.
Arch Neurol 2005;62:1194-1198.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.